Lung Cancers Prompt Pfizer To Revise Exubera Label
Pfizer Inc. said Wednesday that reviews of clinical trial data showed an increase in lung cancer cases in patients who used the inhaled insulin treatment Exubera, leading the drugmaker to update...To view the full article, register now.
Already a subscriber? Click here to view full article